secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2026-06-18T17:17:22+00:00
Accession:  0000078003-26-000087
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer reaffirms FY2026 guidance after CFO transition; revenue $59.5-$62.5B, adj. EPS $2.80-$3.00
--------------------------------------------------------------------------------

- Reaffirms FY2026 revenue guidance of $59.5-$62.5 billion.
- Reaffirms FY2026 adjusted diluted EPS guidance of $2.80-$3.00.
- Reaffirmation follows CFO transition announcement on June 18, 2026.
- Guidance originally introduced Dec 16, 2025 and reaffirmed on Q1 2026 earnings call May 5, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800326000087/0000078003-26-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800326000087/pfe-20260618.htm
  HTML page:      https://secwatch.observer/filing/0000078003-26-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer